Cargando…
Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
OBJECTIVES: To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS. METHODS: Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387646/ https://www.ncbi.nlm.nih.gov/pubmed/37507205 http://dx.doi.org/10.1136/rmdopen-2023-003084 |
_version_ | 1785081929485254656 |
---|---|
author | Zhao, Yuan Huang, Can Qi, Wanting Zhou, Yangzhong Zhao, Jiuliang Wang, Qian Tian, Xinping Li, Mengtao Zhao, Yan Zeng, Xiaofeng |
author_facet | Zhao, Yuan Huang, Can Qi, Wanting Zhou, Yangzhong Zhao, Jiuliang Wang, Qian Tian, Xinping Li, Mengtao Zhao, Yan Zeng, Xiaofeng |
author_sort | Zhao, Yuan |
collection | PubMed |
description | OBJECTIVES: To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS. METHODS: Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models. RESULTS: 362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal. CONCLUSION: The performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately. |
format | Online Article Text |
id | pubmed-10387646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-103876462023-08-01 Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort Zhao, Yuan Huang, Can Qi, Wanting Zhou, Yangzhong Zhao, Jiuliang Wang, Qian Tian, Xinping Li, Mengtao Zhao, Yan Zeng, Xiaofeng RMD Open Autoimmunity OBJECTIVES: To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS. METHODS: Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models. RESULTS: 362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal. CONCLUSION: The performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately. BMJ Publishing Group 2023-07-28 /pmc/articles/PMC10387646/ /pubmed/37507205 http://dx.doi.org/10.1136/rmdopen-2023-003084 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Autoimmunity Zhao, Yuan Huang, Can Qi, Wanting Zhou, Yangzhong Zhao, Jiuliang Wang, Qian Tian, Xinping Li, Mengtao Zhao, Yan Zeng, Xiaofeng Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort |
title | Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort |
title_full | Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort |
title_fullStr | Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort |
title_full_unstemmed | Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort |
title_short | Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort |
title_sort | validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort |
topic | Autoimmunity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387646/ https://www.ncbi.nlm.nih.gov/pubmed/37507205 http://dx.doi.org/10.1136/rmdopen-2023-003084 |
work_keys_str_mv | AT zhaoyuan validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort AT huangcan validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort AT qiwanting validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort AT zhouyangzhong validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort AT zhaojiuliang validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort AT wangqian validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort AT tianxinping validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort AT limengtao validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort AT zhaoyan validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort AT zengxiaofeng validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort |